High-Dose Continuous Nebulized Levalbuterol for Pediatric Status Asthmaticus: A Randomized Trial - 07/08/11
Reprint requests: Joseph J. Zorc, MD, Division of Emergency Medicine, Children’s Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104-4399.Abstract |
Objective |
To assess the use of high-dose continuous levalbuterol (LEV), the single active (R)-enantiomer of racemic albuterol (RAC), in the treatment of status asthmaticus.
Study design |
Children age 6 to 18 years with severe asthma exacerbation were enrolled in this randomized, double-blind trial if they failed initial emergency department (ED) therapy with RAC and systemic steroids. Subjects received equipotent doses of RAC (20 mg/hour) or LEV (10 mg/hour) within a standardized inpatient protocol. Blood samples for measurements of albuterol enantiomer, potassium, and glucose levels were obtained from the first 40 subjects. The median time until discontinuation of continuous therapy was compared using the rank-sum test, and other outcomes were compared using general linear mixed models.
Results |
A total of 81 subjects (40 in the RAC group and 41 in the LEV group) were enrolled; the 2 groups were similar at baseline. Both groups tolerated continuous therapy with similar changes in heart rate and serum potassium and glucose levels but higher serum (S)-albuterol concentrations in the subjects treated with RAC. The median time for continuous therapy was similar in the RAC and LEV groups (18.3 hours vs 16.0 hours), as were the other clinical measures.
Conclusions |
Substituting high-dose continuous LEV for RAC did not reduce the time on continuous therapy and had similar adverse effects in children who had failed initial treatment with RAC.
Le texte complet de cet article est disponible en PDF.Mots-clés : ED, FEV1, LEV, NAEPP, RAC
Plan
| This investigator-initiated study was funded by an unrestricted research grant from Sepracor Inc. The authors declare no other affiliation, financial agreements, or involvement with this or any company that might be considered a conflict of interest. |
|
| ClinicalTrials.gov registration number: NCT00124176. |
Vol 155 - N° 2
P. 205 - août 2009 Retour au numéro
Article précédent
- The Type of LDLR Gene Mutation Predicts Cardiovascular Risk in Children with Familial Hypercholesterolemia
- Ornella Guardamagna, Gabriella Restagno, Elio Rolfo, Cristina Pederiva, Scipione Martini, Francesca Abello, Viviana Baracco, Livia Pisciotta, Elisabetta Pino, Sebastiano Calandra, Stefano Bertolini
- The Use of Exhaled Nitric Oxide in the Diagnosis of Asthma in School Children
- Yakov Sivan, Tali Gadish, Elizabeth Fireman, Ruth Soferman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?